Palisade Bio announces new data from ongoing program evaluating PALI-2108

Palisade Bio (PALI) announced compelling new data from its ongoing clinical program evaluating PALI-2108, a first-in-class, ileocolonic-targeted PDE4 inhibitor, including positive topline results from its Phase 1b open-label cohort in patients with moderate-to-severe UC and colon tissue pharmacokinetic data from the Phase 1a multiple ascending dose cohort. The 7-day, open-label Phase 1b study enrolled five patients with moderate-to-severe UC, receiving titrated BID dosing of PALI-2108. Key highlights include: Achieved 100% clinical response; Mean reduction of 62.8% in modified Mayo score; One patient achieved clinical remission; Fecal calprotectin decreased in 4/5 patients; Plasma hsCRP decreased by 15%